Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence-Reference-Cited by-同舟云学术

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence

Published:2021-07-29 Issue:9 Volume:112 Page:3645-3654
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kitadate Akihiro¹²^ORCID,Terao Toshiki¹^ORCID,Narita Kentaro¹^ORCID,Ikeda Sho²^ORCID,Takahashi Yuto³,Tsushima Takafumi¹,Miura Daisuke¹,Takeuchi Masami¹,Takahashi Naoto²^ORCID,Matsue Kosei¹^ORCID

Affiliation:

1. Division of Hematology/Oncology Department of Medicine Kameda Medical Center Kamogawa Japan

2. Department of Hematology, Nephrology, and Rheumatology Akita University Graduate School of Medicine Akita Japan

3. Department of Life Science Akita University Graduate School of Engineering Science Akita Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15073

Reference35 articles.

1. CD38 antibodies in multiple myeloma: back to the future

2. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

3. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

4. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

5. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

3. An Unusual Increase in the CD38 Marker Observed in a Multiple Myeloma Patient With t(11;14) Translocation: A Case Report;Cureus;2024-07-01

4. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities;Nature Cancer;2024-06-28

5. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review;Journal of Oncology Pharmacy Practice;2023-12-19